Navigation Links
New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
Date:6/24/2014

Singapore, 24 June 2014Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate an immune response to destroy the leukaemia cells and suppress their growth. The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukaemia immunotherapy .

Leukaemia is characterized by the accumulation of cancer cells originating from blood cells, in the blood or bone marrow. Current treatments for leukaemia largely involve chemotherapy to eradicate all cancer cells, followed by stem cell transplants to restore healthy blood cells in the patients.

In a recent study reported in the Journal of Experimental Medicine (JEM) online, the team co-led by Dr Lucia Mori and Prof Gennaro De Libero identified a new class of lipids, methyl-lysophosphatidic acids (mLPA), which accumulate in leukaemia cells. Following which, the team identified a specific group of immune cells, described as mLPA-specific T-cells that are capable of recognising the mLPA in the leukaemia cells. The detection triggers an immune response that activates the T cells to kill the leukaemia cells and limits cancer progression. The efficacy of the T cells in killing leukaemia cells was also demonstrated in a mouse model of human leukaemia.

Thus far, only proteins in cancer cells have been known to activate T cells. This study is a pioneer in its discovery of mLPA, and the specific T cells which can identify lipids expressed by cancer cells. Unlike proteins, lipids in cancer cells do not differ between individuals, indicating that the recognition of mLPA by mLPA-specific T-cells happens in all leukaemia patients. This new mode of cancer cell recognition suggests that the T-cells can potentially be harnessed for a leukaemia immunotherapy that is effective in all patients.

"The identification of mLPA and its role in activating specific T cells is novel. This knowledge not only sheds light on future leukaemia studies, but also complements ongoing leukaemia immunotherapy studies focusing on proteins in cancer cells," said Dr Lucia Mori, Principal Investigator at SIgN. "Current treatments run the risk of failure due to re-growth of residual leukaemia cells that survive after stem cell transplants. T-cell immunotherapy may serve as a complementary treatment for more effective and safer therapeutic approach towards leukaemia."

Professor Laurent Renia, Acting Executive Director of SIgN, said, "At SIgN, we study how the human immune system protects us naturally from infections. We engage in promising disease-specific research projects that ultimately pave the way for the development of treatments and drugs which can better combat these diseases. A pertinent example will be this study; this mode of immune recognition of leukaemia cells is an insightful discovery that will create new opportunities for immunotherapy to improve the lives of leukaemia patients."


'/>"/>

Contact: Tan Yun Yun
tan_yun_yun@a-star.edu.sg
65-682-66273
Biomedical Sciences Institutes (BMSI)
Source:Eurekalert

Related medicine news :

1. Newly discovered brown fat cells hold possibilities for treating diabetes, obesity
2. Lipids help to fight leukemia
3. Leukemia drug found to stimulate immunity against many cancer types
4. One in 4 children with leukemia not taking maintenance medication, study shows
5. Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
6. Tiny mutation triggers drug resistance for patients with one type of leukemia
7. Major discovery on the mechanism of drug resistance in leukemia and other cancers
8. New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
9. Novel target found for chemotherapy-resistant leukemia cells
10. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
11. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... Nike Rugby Camp's success is due in large part ... of Elite Rugby Camps and current Nike Camp director, has offered an all abilities ... , “I’m excited for our eighth summer here in San Diego,” says Willis. "We ...
(Date:5/4/2016)... ... 2016 , ... All-Star Insurance of Northeast TX has announced ... their local community. The agency pledges to select a new beneficiary every 60 ... bring awareness to important local causes with fundraising and other support, by forming ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... at their office. Wisdom tooth removal, a common dental procedure, is performed for many ... are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... small and compact tactical (6.7 inch) dual-light flashlights in models NSP-9842XL and ... NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 batteries to produce ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis ... of two patients who tell their personal story and encourage those at risk to get ... Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... -- Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical line ... of recovery for a variety of clinical conditions. Founded in 2013, Forté spent more ... Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... NEW YORK , May 2, 2016 /PRNewswire/ ... Series B financing of Graybug Vision, Inc. Graybug ... to developing therapies that may transform care for ... and glaucoma.  Graybug Vision,s technology was first developed ... out into a startup venture. ...
Breaking Medicine Technology: